ResMed (RMD) return on equity (ROE)

Return on equity · fiscal 2026
23.1%

ResMed (RMD) earned a return on equity of 23.1% in fiscal 2026 (the year ended June 30, 2026). That is 0.3 percentage points lower than the 23.5% of fiscal 2025. Figures as of 17 Nov 2026, 20:55 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2026
23.1%
Change on fiscal 2025
−0.3 pts
Highest on record
24.9%fiscal 2020
Lowest on record
13.1%fiscal 2011
Fiscal years on record
182009–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

ResMed return on equity (ROE), in more detail

Across the 18 fiscal years on record (2009–2026), the highest was 24.9% in fiscal 2020 and the lowest 13.1% in fiscal 2011. The fiscal 2026 figure is higher than in 82% of the 17 earlier fiscal years on record, whose median is 19.5%.

History · 18 fiscal years

Return on equity by fiscal year

ResMed return on equity (ROE), year by year

ResMed (RMD) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202623.1% 0.3 pts down
202523.5% 2.5 pts up
202421.0% 0.7 pts down
202321.7% 1.5 pts down
202223.2% 6.7 pts up
202116.4% 8.5 pts down
202024.9% 5.4 pts up
201919.5% 4.2 pts up
201815.3% 2.1 pts down
201717.5% 3.3 pts down
201620.8% 1.4 pts down
201522.2% 2.6 pts up
201419.6% 0.6 pts up
201319.1% 3.2 pts up
201215.9% 2.7 pts up
201113.1% 1.6 pts down
201014.8% 1.6 pts up
200913.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on RMD

ResMed, figure by figure

ResMed (RMD) overview: price, valuation and scorecardAll health care companies by market value

ResMed return on equity (ROE): questions and answers

What is ResMed's return on equity?

ResMed (RMD) earned a return on equity of 23.1% in fiscal 2026 (the year ended June 30, 2026). That is 0.3 percentage points lower than the 23.5% of fiscal 2025.

Is ResMed's return on equity high or low compared with its own history?

The fiscal 2026 figure is higher than in 82% of the 17 earlier fiscal years on record, whose median is 19.5%.

What are the highest and lowest return on equity figures on record for ResMed?

Across the 18 fiscal years on record (2009–2026), the highest was 24.9% in fiscal 2020 and the lowest 13.1% in fiscal 2011.

How is ResMed's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ResMed (RMD) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/RMD/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.